OPG (Osteoprotegerin) belongs to the TNF receptor super-family and is implicated in bone remodeling and in the atherosclerotic process. This molecule acts as a decoy receptor for the RANKL (Receptor Activator of Nuclear Factor-KappaB Ligand), inhibiting binding of RANKL to its receptor, RANK. OPG acts as a soluble neutralizing receptor of TRAIL (TNF-Related Apoptosis-Inducing Ligand), an anti-inflammatory molecule with anti-atherosclerotic properties. Mostly implicated in bone remodeling, the RANK/RANKL/OPG axis is involved in immune and vascular system. OPG has been associated with increased risk of atherosclerotic disease in the general population. OPG has also been associated with increased pulse wave velocity, progression of arterial calcification and with mortality in both end-stage renal failure patients as well as the general population.
